Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NovaTests

Financiado

Cerrado

The first predictive test for radio sensitivity. A step towards an improved and...

The first predictive test for radio sensitivity. A step towards an improved and personalised radiation therapy cancer treatment. Each year, two out of three cancer patients undergo radiation therapy, meaning close to 1.5M patients in Europe and 2M in the US. However, scientific evidences prove a direct link between radiation therapy and several serious late... ver más

30/09/2018

NovaGray

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

NOVAGRAY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-09-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

NovaGray

50.00K€ | Lider

SOLAR MEMS TECHNOLOGIES

265.30K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CPP2021-008368 RADIOTERAPIA DE PRECISIÓN: FIRMA MOLECULAR PREDICTIVA PARA R... 288K€ Cerrado

MMpredict Validation of a personalised medicine tool for Multiple Myel... 4M€ Cerrado

RTC-2016-5674-1 Determinación de perfiles metabolómicos en el diagnóstico pr... 482K€ Cerrado

PDC2022-133056-I00 TRADUCIENDO LA BIOLOGIA TUMORAL EN MEDICINA PERSONALIZADA: D... 133K€ Cerrado

REQUITE Validating predictive models of radiotherapy toxicity to imp... 8M€ Cerrado

VALIDACIÓN Y CERTIFICACIÓN DE UN TEST NUTRIGE... VALIDACIÓN Y CERTIFICACIÓN DE UN TEST NUTRIGENÉTICO PREDICTI... 359K€ Cerrado

Duración del proyecto: 4 meses Fecha Inicio: 2018-05-12
Fecha Fin: 2018-09-30

Líder del proyecto

NOVAGRAY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Each year, two out of three cancer patients undergo radiation therapy, meaning close to 1.5M patients in Europe and 2M in the US. However, scientific evidences prove a direct link between radiation therapy and several serious late effects. This because patient’s tolerance to radiation vary significantly and radiotherapy affects indiscriminately both healthy and cancer cells, damaging also active working cells, tissues or organs around the tumour. There is, therefore, an unmet clinical need to tailor treatments to each patient’s unique biology. NovaTests are the first predictive radio-sensitivity tests for cancer treatment. By analysing a simple blood sample, in one week time, we can determine with high accuracy (over 90%) not only whether a patient is sensitive or not to radiation but also how sensitive the patient is. We allow for more efficient treatments and improved quality of cancer survivors, not only during radiation treatments but for the rest of their lives. Our first test, the NovaGray Breast® is aimed at measuring radiosensitivity for breast cancer patients. It meets all regulatory requirements of the 98/79 directive pertaining to the in-vitro diagnostic medical devices, has been stamped with the CE marking in February 2016. So far, €0.5M million have been invested into the development and testing of technology to ensure its robustness and efficiency and move into the next stage of tests development and validation. Within the overall project, we intend to scale-up the process by automating it and run a multi-centre clinical trial to validate the reliability of the test. Further ongoing developments include the extension of the technology to prostate and lung cancers. The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of NovaTests and their market uptake.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores